Get the Stockscreener App
9.32
13.38%
1.10
After Hours:
9.50
0.18
+1.93%
Camp 4 Therapeutics Corp stock is traded at $9.32, with a volume of 113.27K.
It is up +13.38% in the last 24 hours and up +2,230% over the past month.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$8.22
Open:
$8.3
24h Volume:
113.27K
Relative Volume:
0.57
Market Cap:
$181.79M
Revenue:
$264.74M
Net Income/Loss:
$-101.35M
P/E Ratio:
-16.35
EPS:
-0.57
Net Cash Flow:
$-3.08M
1W Performance:
-18.03%
1M Performance:
+2,230%
6M Performance:
+153.26%
1Y Performance:
+59.53%
1-Day Range:
$8.26
$9.8099
1-Week Range:
$7.80
$11.29
52-Week Range:
$0.3901
$87.50
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
-
Address
-
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
Camp4 stock gains after earning bullish views (CAMP:NASDAQ) - Seeking Alpha
William Blair upbeat on CAMP4 shares with Outperform rating - Investing.com
Leerink sets stock target for CAMP4, cites broad UCD treatment potential - Investing.com India
JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech - Investing.com India
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology - Investing.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Camp4 Therapeutics sees $8.4 million stock purchase by Northpond Ventures - Investing.com India
Camp4 Therapeutics sees $7.99m stock purchase by investors By Investing.com - Investing.com India
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com India
CAMP4 Rings the Opening Bell - Nasdaq
Insider Trading Activity Tuesday: Top Buys and Sells in US Stocks Revealed - Investing.com
Camp4 Therapeutics sees $9.99 million stock purchase by Polaris - Investing.com
Camp4 Therapeutics sees $9.99 million stock purchase by 5AM Ventures - Investing.com Australia
Camp4 Therapeutics director Nashat Amir buys $9.99m in stock - Investing.com India
Camp4 Therapeutics director Nashat Amir buys $9.99m in stock By Investing.com - Investing.com Australia
Camp4 Therapeutics director Andrew Schwab buys $9.99m in stock - Investing.com
Camp4 Therapeutics director Andrew Schwab buys $9.99m in stock By Investing.com - Investing.com South Africa
Upstream Bio and Camp4 and Ceribell Transactions - William Blair
CAMP4 Therapeutics’ $75 Million IPO - Global Legal Chronicle
Opening Day: Another trio of biotech IPOs make Friday debut - Yahoo Finance
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 stock edges up 2% following $75M IPO - MSN
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception - BioCentury
Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs - Scrip
Upstream Bio Shares Rise 26% to Lead Burst of Life Sciences IPOs - MSN
6 Firms Guide IPO Trio From Biotech, Medical Device Cos. - Law360
Form 424B4 Camp4 Therapeutics Corp - StreetInsider.com
CAMP4 stock edges up 2% following $75M IPO (NASDAQ:CAMP) - Seeking Alpha
Camp4 Therapeutics Opens At $11.16, IPO Priced At $11 - Investing.com
CAMP4's turn to "dark side" shows promise, with $75 million IPO - The Pharma Letter
CAMP4 Therapeutics prices $75MIPO at $11 per share - MSN
RNA biotech CAMP4 Therapeutics prices IPO below the range at $11; adds shares to keep deal size at $75 million - Renaissance Capital
CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh By Investing.com - Investing.com South Africa
CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh - Investing.com
CAMP4 Therapeutics To Debut On Nasdaq Today - RTTNews
CAMP4 Announces Pricing of Initial Public Offering - ForexTV.com
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
| Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
| Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| 5AM Partners VI, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Nashat Amir | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| Schwab Andrew J. | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Cohenour Jason | Director |
Jun 05 '24 |
Sale |
0.83 |
8,640 |
7,176 |
0 |
| Cohenour Jason | Director |
Mar 05 '24 |
Option Exercise |
0.00 |
7,824 |
0 |
10,962 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):